Should You Buy CareDx Inc (CDNA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
CDNA is not a good buy right now for a beginner long-term investor who doesn’t want to wait for better clarity. The stock is in a bullish technical uptrend near resistance, but near-term risk/reward looks less compelling due to heavy insider selling, lingering reimbursement/policy uncertainty (MolDX LCD), and a recent analyst downgrade. A more attractive long-term entry is likely after the 2026-02-26 earnings and/or clearer reimbursement visibility.
Technical Analysis
Trend/Setup: Bullish moving-average structure (SMA_5 > SMA_20 > SMA_200) supports an ongoing uptrend. Momentum: MACD histogram is positive (0.0433) but contracting, implying upside momentum is weakening rather than accelerating. RSI_6 ~57.8 is neutral—no clear overbought/oversold edge. Levels: Pivot ~20.503 is the key line to hold; immediate resistance is R1 ~21.269 then R2 ~21.742. Supports are S1 ~19.737 then S2 ~19.264. With price ~20.78, the stock is closer to resistance than support, which reduces immediate upside for an impatient buyer.
Intellectia Proprietary Trading Signals: No signal on given stock today. (AI Stock Picker: no signal; SwingMax: no recent signal.)
Analyst Ratings and Price Target Trends
Recent trend: sentiment cooled. On 2026-01-06, Craig-Hallum downgraded CDNA from Buy to Hold with a $26 target, citing less compelling risk/reward after the share recovery and noting 2026 revenue/long-term growth depend heavily on the final MolDX LCD; also flagged risk Q4 2025 volumes could come in below guidance midpoint. Earlier, on 2025-12-15, Wells Fargo kept an Equal Weight rating but raised its price target to $18 from $14, reflecting improved setup yet still not a high-conviction Buy.
Wall Street pros: strong revenue growth, improving gross margin, and potential upside if reimbursement clarity improves.
Wall Street cons: reimbursement/policy uncertainty is a primary overhang, recent downgrade reduces momentum, and near-term volume/profitability concerns remain.
Influential/Politician trading: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast CDNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 18 USD with a low forecast of 18 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CDNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 18 USD with a low forecast of 18 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 20.460
Current: 20.460
